Prognostic prediction and treatment strategy in hepatocellular carcinoma
By Jordi Bruix1 , 2, J. Llovet. Hepatology, 2002
1,135 citations recorded by the source corpus.
Subfields: Epidemiology, Hepatology
View Paper: https://www.semanticscholar.org/paper/26c12eb800048b69018c330f3ba3755594bd27a6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
- Jordi Bruix1 , 2
- J. Llovet
- V. Mazzaferro
- Peter R. Galle
- Andrew X. Zhu
- Riccardo Lencioni
- M. Bernardi
- M. Sherman
In Hepatology
- J. Llovet
- Jordi Bruix1 , 2
- Riccardo Lencioni
- V. Mazzaferro
- Andrew X. Zhu
- Peter R. Galle
- T. de Baère
- T. Greten
Citations in the corpus
- Management of hepatocellular carcinoma: An update (2011, neutral): “2.(17,19,194,200) The strategy combines in a single proposal staging, indicated treatment and estimation of prognosis, and it can be applied to the majority of patients evaluated for HCC.”
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study (2009, background): “Barcelona Clinic Liver Cancer (BCLC) tumor staging [3, 4] combines the stage of liver disease, tumor stage, clinical performance, and treatment options and is endorsed by the European Association for the Study of Liver Disease (EASL) and the American Association for the Study of Liver Disease (AASLD”
- Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma (2014, methodology): “Tumor stage was determined according to the BarcelonaClinic LiverCancer (BCLC) stage (21).”
- EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “In 2000, there was great enthusiasm for LDLT, and it was estimated that it would represent a significant proportion of the patients transplanted with HCC [243].”
- Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma (2010, neutral): “with larger HCCs [245, 246].”
- EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “In 2000, there was great enthusiasm for LDLT, and it was estimated that it would represent a significant proportion of the patients transplanted with HCC [243].”